Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Howes

Showing results (381-390 of 443) with videos related to

Pageof 45
Sort By:
Journal of Psychopharmacology (Oxford, England)|December 15, 2017
Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for PsychopharmacologyOliver D Howes, Maria Rogdaki, James L Findon, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 12, 2014
Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosisAlice Egerton, James M Stone, Christopher A Chaddock, et al.
Frontiers in Neurology|November 12, 2020
Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An <i>in vivo</i> PET Study With Neuropathological ComparisonPaul Wright, Mattia Veronese, Ndabezinhle Mazibuko, et al.
Schizophrenia Bulletin|January 5, 2021
Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant SchizophreniaGrant McQueen, Kyra-Verena Sendt, Amy Gillespie, et al.
JAMA Psychiatry|December 10, 2025
Role of Serotonin in the Neurobiology of Schizophrenia and Association With Negative SymptomsMartin Osugo, Thomas Whitehurst, David Erritzoe, et al.
Psychological Medicine|September 9, 2016
Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychosesJ Lally, O Ajnakina, M Di Forti, et al.
Schizophrenia (Heidelberg, Germany)|March 3, 2022
Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophreniaFanni Krajner, Laila Hadaya, Grant McQueen, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 9, 2026
Does a monoclonal antibody targeting immune cells affect glutamatergic level in schizophrenia? A multimodal PET/MRS brain imaging studyGuy Hindley, Yuya Mizuno, Katherine Beck, et al.
Nature Communications|August 15, 2018
Post-polymerisation functionalisation of conjugated polymer backbones and its application in multi-functional emissive nanoparticlesAdam Creamer, Christopher S Wood, Philip D Howes, et al.
Psychopharmacology|April 21, 2022
The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging studyMichael A P Bloomfield, Yumeya Yamamori, Chandni Hindocha, et al.
Pageof 45

Showing results (381-390 of 443) with videos related to

Sort By:
Pageof 45
Journal of Psychopharmacology (Oxford, England)|December 15, 2017
Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for PsychopharmacologyOliver D Howes, Maria Rogdaki, James L Findon, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 12, 2014
Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosisAlice Egerton, James M Stone, Christopher A Chaddock, et al.
Frontiers in Neurology|November 12, 2020
Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An <i>in vivo</i> PET Study With Neuropathological ComparisonPaul Wright, Mattia Veronese, Ndabezinhle Mazibuko, et al.
Schizophrenia Bulletin|January 5, 2021
Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant SchizophreniaGrant McQueen, Kyra-Verena Sendt, Amy Gillespie, et al.
JAMA Psychiatry|December 10, 2025
Role of Serotonin in the Neurobiology of Schizophrenia and Association With Negative SymptomsMartin Osugo, Thomas Whitehurst, David Erritzoe, et al.
Psychological Medicine|September 9, 2016
Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychosesJ Lally, O Ajnakina, M Di Forti, et al.
Schizophrenia (Heidelberg, Germany)|March 3, 2022
Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophreniaFanni Krajner, Laila Hadaya, Grant McQueen, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 9, 2026
Does a monoclonal antibody targeting immune cells affect glutamatergic level in schizophrenia? A multimodal PET/MRS brain imaging studyGuy Hindley, Yuya Mizuno, Katherine Beck, et al.
Nature Communications|August 15, 2018
Post-polymerisation functionalisation of conjugated polymer backbones and its application in multi-functional emissive nanoparticlesAdam Creamer, Christopher S Wood, Philip D Howes, et al.
Psychopharmacology|April 21, 2022
The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging studyMichael A P Bloomfield, Yumeya Yamamori, Chandni Hindocha, et al.
Pageof 45